Source comparison
CJC-1295 No DAC & Ipamorelin Research Comparison
Animal. Receptor Binding Rat pituitary tissue assays GHRH/ghrelin receptor affinity (Ki values) Single timepoint Establishes molecular mechanism No in vivo translation Animal. Pharmacokinetics Sprague Dawley rats, IV or SC injection GH secretion pattern, half-
This comparison does not assign a generated winner or score.
- Animal. Receptor Binding
- Rat pituitary tissue assays
- GHRH/ghrelin receptor affinity (Ki values)
- Single timepoint
- Establishes molecular mechanism
- No in vivo translation
- Animal. Pharmacokinetics
- Sprague Dawley rats, IV or SC injection
- GH secretion pattern, half-life, clearance rate
- 6–24 hours
- Precise dose-response curves
- Species metabolic differences
- Animal. Long-Term Outcomes
- C57BL/6 mice, 8–12 weeks dosing
- Body composition (DEXA), IGF-1 levels, lean mass
- 8–12 weeks
- Proof-of-concept for sustained effect
- Controlled diet/environment
- Human. Phase I Safety
- 12–24 healthy adult volunteers
- Adverse events, cortisol/prolactin response
- Single dose to 7 days
- Confirms safety at tested doses
- No efficacy endpoints
- Human. Phase II PK
- 18–50 participants, single or multi-dose
- GH peak timing, IGF-1 elevation, dose linearity
- 24 hours to 4 weeks
- Validates dosing schedule
- Too short for body composition
- Human. Observational Use
- Retrospective analysis of research protocols
- Self-reported outcomes, compliance patterns
- Variable (3–6 months typical)
- Real-world adherence data
- No control group, high bias